Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03385486
Title Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Taiga Biotechnologies, Inc.
Indications

melanoma

Therapies

TBX-3400

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.